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Abstract 
Skin offers an easily accessible and convenient site for the administration of 
drugs. Therefore, the development of injectable formulations with controlled drug release 
properties are now expected to deliver middle- and large-size biomolecules. In the present 
study, formulations mainly composed of a novel polyol ester with an isoprenoid side 25 
chain; mono-O-(5,9,13-trimethyl-4-tetradecenyl) glycerol ester (MGE), that was capable 
of forming a non-lamellar liquid crystal (NLLC), were prepared with different types of 
phospholipid. Then, factors that affected the release of a model entrapped drug, 
fluorescein-isothiocyanate dextran (FD-4, M.W. 4,000), from the MGE formulations were 
analyzed with multi-regression analysis. In addition, self-assembly of the NLLC structure 30 
was investigated using small-angle X-ray scattering analysis after contacting the MGE 
formulations with water. NLLC-forming ability of the formulations after s.c. injection 
into rats was also confirmed using microscopic observations. FD-4 concentrations in 
blood were determined after s.c. injection of the MGE formulations. The injectable MGE 
formulations successfully constructed NLLC structures to form a sponge-like gel after 35 
contact with water in vitro and in vivo (in rats) as well. In in vitro conditions, the amount 
of FD-4 released from the formulations was altered by changing the type and 
concentration of phospholipid in the MGE formulations and can be expressed with 
parameters such as MGE content and interplanar spacing of the NLLC. A significantly 
sustained FD-4 level in the blood was observed after s.c. injection of the formulations. 40 
These results suggested that injectable MGE formulations may have the potential to 
achieve controlled release profiles of drugs after s.c. injection. 
 
 
Keywords: Non-lamellar liquid crystal injectable formulation, controlled release, middle- 45 




Biopharmaceuticals have become the mainstream in the current worldwide drug 
market. The most convenient dosage forms, oral formulations, however, are not available 50 
for many biopharmaceuticals due to their low bioavailability from the GI tract. Instead of 
oral formulations, transdermal drug delivery, including intradermal (i.d.) and 
subcutaneous (s.c.) administration, are of increasing interest as alternative administration 
routes. These routes of administration have advantages such as the avoidance of first-pass 
effects, effective delivery of drugs with low oral bioavailability, and the utilization of 55 
various types of dosing vehicles compared with intravenous (i.v.) administration (Park, 
2014). Recently, minimally invasive i.d and s.c. administrations of drugs have become 
possible through the technological development of micro-electromechanical systems. 
Thus, many reports have been published on physical devices such as microneedle arrays, 
needle-free injection, and thermalporation, which can directly administer 60 
biopharmaceuticals into i.d and s.c layers of tissues (Santos et al., 2014). 
Several biocompatible formulations such as liposomes, poly (lactic-co-glycolic 
acid) microspheres, and hyaluronic acid microspheres with controlled drug release 
properties can improve therapeutic effects, reduce side effects, and provide a better 
quality of life (Guo et al., 2017; Angst et al., 2006; Wilczewska et al., 2012; Bhosale et 65 
al., 2013). Therefore, the combination of these physical devices and biocompatible 
formulations may become the most amenable methods for the self-administration of 
biopharmaceuticals by patients (Lee et al., 2018). 
Lyotropic non-lamellar liquid crystals (NLLCs), such as phytantriol (PHY) and 
glyceryl monooleate (GMO), based on the self-assembly of amphiphilic lipids in water, 70 
have gained increasing attention as next-generation nanocarriers for drug delivery. The 
critical packing parameter (CPP) determines the geometric self-assembly structure; i.e., 
CPP < 1/3 for spherical micelles, 1/2–1 for bicontinuous cubic (Q1), »1 for a lamella 
structure, ≥1 for a reversed bicontinuous cubic phase (Q2), and >1 for reversed hexagonal 
phase (H2). Phospholipids can be used to form liposomes, which are typical 75 
biocompatible drug carriers. On the other hand, GMO and PHY form NLLCs states Q2 
and H2 in water (Shi et al., 2015). NLLCs have complex large internal surface areas and 
aqueous networks. Thus, they can encapsulate a wide range of drugs (i.e. hydrophilic, 
lipophilic, and amphiphilic) with a high entrapment efficacy. In addition, these 
characteristics are preferable for the controlled release of entrapped drugs (Otte et al., 80 
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2018; Rajabalaya et al., 2017; Chen et al., 2014). Moreover, improvement of the physical 
stability of entrapped proteins has been reported using NLLCs (Kulkarni et al., 2011; 
Evenbratt and Ström., 2017; Boge et al., 2016). The structures of NLLCs can be changed 
by many factors, including temperature, pH, water content, and different additives 
(Kulkarni et al., 2011; Lim et al., 2015; Mei et al., 2018; Wu et al., 2014; Butreddy et al., 85 
2015). Because phase structure-related drug-delivery systems have been broadly 
published, it becomes possible now to fabricate intelligent drug carriers with NLLCs.  
In the present study, easily self-administrable formulations with sustained drug 
release properties have been investigated using NLLC-forming lipids. A novel 
amphiphilic lipid, mono-O-(5,9,13-trimethyl-4-tetradecenyl) glycerol ester (MGE) (0.47 90 
Pa・s at a share rate of 10 s-1)was used instead of GMO and PHY, because MGE is easy 
to handle due to its relatively low viscosity at room temperature. In addition, an 
isoprenoid type fatty chain in the MGE structure exhibited a highly self-organized NLLC 
structure with closed packing at the interface over a wide range of temperatures (Kadhum 
et al., 2017; Kadhum et al., 2017). 95 
Drug absorption rate is closely characterized by the drug release rate; therefore, 
it is important to understand the release rate of entrapped drugs to optimize the 
formulation. In the present study, an s.c. injectable formulation with a sustained drug 
release rate of a model hydrophilic high molecular weight of compound, fluorescein 
isothiocyanate–dextran (FD-4; average molecular weight 4,000), was developed by 100 
altering the formulation by adding phospholipids to an NLLC-forming lipid, MGE. 
 
2. Materials and Methods 
2.1. Materials 
FD-4 was obtained from Sigma-Aldrich (St. Louis, MO, USA). 1,2-Dimyristoyl-105 
sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) were purchased from NOF Corporation (Tokyo, 
Japan). MGE was kindly provided by Farnex Inc. (Yokohama, Japan). Polyoxyethylene 
sorbitan monooleate (Tween 80) was obtained from Tokyo Chemical Industry (Tokyo, 110 
Japan). All other regents were used without further purification.  
 
2.2. Animal experiments 
 5 
Male Wistar rats weighing about 190–230 g (8 weeks old) were obtained from 
Ishikawa Laboratory Animals (Fukaya, Saitama, Japan). Rats were housed in a room at 115 
25 ± 2°C and the light was turned on and off every 12 h. The rats had freely available 
water and diet (obtained from Oriental Yeast Co., Ltd., Tokyo, Japan). All animal feeding 
and experiments were approved by the Institutional Animal Care and Use Committee of 
Josai University (Sakado, Saitama, Japan).  
 120 
2.3. Preparation of MGE formulations 
Table 1 shows the composition of the prepared MGE formulations. MGE, 
ethanol and Tween 80 were added to a glass vial at 60°C and stirred with a hot-plate 
magnetic stirrer (RSH-1DN, AS ONE Corp., Osaka, Japan) at 500 rpm for 5 min. Then, 
each of the weighed phospholipids was added to a vial at 60°C and further mixed at 700 125 
rpm for 1 h to prepare homogeneous base formulations. After cooling to room 
temperature, FD-4 was dispersed thoroughly using a spatula in the base formulation to 
obtain a suspension with a concentration of 15.6 mg/mL. Ethanol and Tween 80 were 
used as additives to completely dissolve each phospholipid in the MGE formulations. 
Msc48 and Mpc48 became solid state when DSPC and DPPC were added to the 130 
formulation at their concentrations higher than 36%. Thus, Msc48 and Mpc48 were not 




2.4. Polarized microscope observation 
Polarized images were observed using a microscope (VHX-5000, Keyence 
Corp., Osaka, Japan). The observed samples were prepared by applying 10 µL of each 
MGE formulation on a slide glass, followed by dropping an equal volume of phosphate-
buffered saline (PBS; 1/30 M PBS, pH 7.4) onto the formulation. Polarized images were 140 
acquired 15 min after applying PBS to the formulation. All samples were observed on a 
glass slide with a cover glass at room temperature. 
 
2.5. Small angle X-ray scattering (SAXS) analysis 
SAXS measurements of the MGE formulations were carried out using a Rigaku 145 
NANOViewer SAXS system equipped with an X-ray generator (Akishima, Tokyo, 
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Japan) (Cu Kα radiation, λ = 1.5418 Å) operated at 30 kV and 40 mA. The camera focal 
length was set to 700 mm. The scatter pattern was acquired on a blue imaging plate for 1 
h. The obtained pattern was analyzed using a Rigaku NANO-Solver program. All 
processes related to the measurement operation were conducted by a qualified researcher 150 
at Kanazawa University (Kanazawa, Ishikawa, Japan). Crystalline interplanar spacing, d, 
was determined, in accordance with the Bragg equation. 
 
2.6. In vitro release tests 
A Pur-A-Lyzer™ Mini Dialysis Kit Mini (Sigma Aldrich) was used to perform 155 
the FD-4 release tests (Báez-Santos et al., 2016). After application of 100 µL of each 
formulation into a dialysis tube (molecular cut-off; 12,000), the sample was placed into a 
25 mL tube (MINI-2362-025, AGC Techno Glass Co. Ltd., Yoshida, Shizuoka, Japan) 
filled with 20 mL PBS containing 0.01% sodium azide as a preservative in the receiver 
solution. In vitro FD-4 release was conducted at room temperature (25 ± 2°C) 160 
(Rosenbaum et. al., 2010, Clogston et. al., 2005) with shading using aluminum foil. The 
receiver solution was periodically sampled, and the same volume of fresh PBS containing 
sodium azide was added to the receiver compartment to maintain a constant volume. The 
water absorption ratio was determined by the formulation weights before and 48 h after 
placing into a 5 mL tube filled with PBS containing 0.01% sodium azide. 165 
 
2.7. In vivo experiments 
Wistar rats were anesthetized with isoflurane (Pfizer, New York, NY, USA). 
The right jugular vein was exposed, and a silicone tube catheter with a 0.5-mm internal 
diameter and a 1.0-mm outer diameter (Silascon 100-00N, Kaneka Medics, Osaka, Japan) 170 
were inserted into the vein. The catheter was prefilled with sterilized saline containing 
heparin (50 IU/mL; Mochida, Tokyo, Japan). The free ends of the catheter were dorsally 
externalized, which permitted the experiment to be conducted in unanesthetized and 
unrestrained conditions. The rats were used after a recovery period. The MGE 
formulation (100 µL) containing FD-4 was administered to the shaved back skin on the 175 
right side of rats using a 1 mL disposal syringe (Terumo Corp., Tokyo, Japan) with a 23G 
needle (Terumo Corp.). Blood sampling was conducted periodically until 48 h after 
administration of the formulation. Plasma was obtained after centrifugation of blood at 
21,500 × g for 5 min at 4°C. The obtained plasma was kept in a freezer at -20°C. Plasma 
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(100 µL) was thoroughly mixed with PBS (400 µL) and centrifuged (21,500 × g for 5 180 
min at 4°C) to obtain the supernatant. The FD-4 concentration was determined at 
excitation and emission wavelengths of 485 and 535 nm, respectively, using a 
fluorescence spectrophotometer (RF5300PC, Shimadzu, Kyoto, Japan). 
 
2.8. Observation of FD-4 disposition 185 
A 1.5 cm ´1.5 cm area of skin was excised from the rat back where the MGE 
formulation was administered, embedded in frozen section compound (SCEM; Leica 
Microsystems GmbH, Wetzlar, Germany) and frozen at −80°C. The frozen skin was cut 
into 10-μm-thick sections using a cryostat (CM3050S, Leica Microsystems, GmbH, 
Wetzlar, Germany). The center part of the administration site was observed using a 190 
confocal laser scanning microscope (Fluoview FV1000, software: FV10-ASW, Olympus 
Corp., Tokyo, Japan). 
 
2.9. In vivo imaging after administration of FD-4 in rats 
Fluorescence images of administered FD-4 were observed using an IVIS 195 
Spectrum (Perkin Elmer, Waltham, MA, USA) with a 465-nm excitation filter and a 520-
nm emission filter,  and recorded before injection (0 min) and 1 and 2 days after 
administration. The epi-illumination settings for image acquisition were exposure time (2 
s), binning (medium), f-stop (2), and field of view (22 cm). For three-dimensional (3D) 
image acquisition, fluorescence and photographic images were acquired and overlaid. 200 
Data analysis was performed using Living Image version 4.7 software (SAS Institute Inc. 
Cary, NC, U.S.A.).  
 
2.10. Multi-regression analysis 
Multi-regression analysis was carried out using JMPÒ Pro (ver. 14.1.0, SAS 205 
Institute, Cary, NC, USA). Stepwise regression analysis was employed to develop a 
regression, and the most suitable descriptors were selected using coefficient of variation 
(r2). Separately, stepwise regression was used to select the best factors to predict FD-4 
release ratio, based on the r2 value, from descriptors retrieved from measured parameters. 
 210 
2.11. Statistical analysis 
 8 
All experimental measurements were performed at least in triplicate. Values are 
expressed as the mean ± standard deviation (SD). Statistical significance of differences 
in FD-4 release and blood concentration of FD-4 were examined using one-way analysis 
of variance (ANOVA) followed by the Tukey–Kramer post-hoc test. The significance 215 




Figure 1 shows the water absorption ratio in the MGE formulations. Most of the 
formulations in this experiment absorbed about 30% water. Mmc48 showed the highest 220 
water absorption among the MGE formulations, and only Mmc48 had a significantly 
higher (p< 0.05) water absorption ratio compared with neat MGE formulations, M. 
Figure 2 shows polarized images 15 min after adding PBS to the prepared 
formulations. All preparations showed polarized images. The corresponding SAXS 
results are illustrated in Fig. 3, and the spacing lattices are summarized in Table 2. 225 
Formulation M exhibited an H2 structure. Msc12, Moc12, and Moc24 displayed H2 
structures as well. Msc12 had Pn3m as well as the H2 structures, whereas the other 
formulations showed only Pn3m structures. Thus, the liquid crystal structure of MGE can 
be modified by the type and concentration of phospholipids. The interplanar spacing was 
also changed by the type and amount of phospholipid; interplanar spacing increased with 230 
the increasing amount of phospholipid in the formulation, except for Mmc.  
 
(Figures 1 - 3) 
(Table 2) 
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Figure 4 shows the amount of FD-4 released from the MGE formulations over 
48 h. Drug release was confirmed from all formulations without an obvious burst of 
drug release (time course data not shown). The total amount of FD-4 released from 
Mmc increased with an increase in DMPC content, except for Mmc48. Significantly 
increased FD-4 release (p< 0.05) was observed in Mmc24, Mmc36, and Mmc48 240 
compared with M. Almost similar results were observed in the other formulations. The 
highest FD-4 releases were observed at the highest phospholipid content in Mpc, Msc, 
and Moc. In addition, the effect of addition of ethanol and Tween 80 to the formulation 
(composition; M: ethanol: Tween= 88:10:2) was investigated on the FD-4 release. No 






Figure 5a shows a relationship between the FD-4 release from the MGE 250 
formulation and their interplanar spacings. A good relationship (r2=0.78) was confirmed 
between them. In addition, logarithm of the amount of FD-4 released was well expressed 
(r2=0.82) using the following equation (eq. 1, Fig. 5b);  
 
log $%4!"#"$%"& = 0.434 ∙ ,- − 0.020 ∙ 01 − 0.027 ∙ 31 − 0.018 ∙ 611 + 0.304 ∙255 
6% + 0.709                                                      (eq. 1) 
 
where IS, MC, PC, NNC, and ND are interplanar spacing, M content, phospholipid 
content, number of carbon chains in the phospholipid, and number of double bonds in the 
carbon chain, respectively. The root mean square error (RMSE) was 0.144. From this 260 
equation, the increasing phospholipid content decreased FD-4 release, and ND increased 




Although the construction of NLLC was confirmed in water-rich conditions, 
further investigations are needed to clarify the drug disposition and the construction of 
the NLLC structure in the skin after topical administration. Figure 6 shows whole animal 
images obtained from IVIS Spectrum 0, 1, and 2 days after s.c. administration of neat 
MGE formulation into the right side of the back in rats. Figure 6 shows the tissue 270 
distribution after s.c. injection of M and collected samples from the injected area 24 h 
after administration. Fluorescence images showed the FD-4 disposition at the 
administration site over at least 2 days.  
FD-4 distribution and construction of NLLC gel form after s.c. injection were 
confirmed by microscopic observation of the skin section (Fig. 7a and b) and gel 275 
recovered from the administration site (Fig. 7c). A green color distribution derived from 
FD-4 was confirmed 1 h after administration (Fig. 7a), and its localization was also 
observed over at least 24 h (Fig. 7b). A bright fluorescence color was detected across the 
whole subcutis 1 h after administration, whereas the green color was observed mainly in 
the shallow subcutis 24 h after administration. A sponge-like, yellow-colored, semi-solid 280 
gel was collected 48 h after the administration of M (Fig. 7c). The gel form was confirmed 
at least over 7 days at the administration site, and completely disappeared by 1 month 
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after administration (data not shown).  
 
(Figures 6 and 7) 285 
 
A semi-solid gel was constructed after s.c. injection of the formulation. The FD-
4 concentration–time profile was further investigated in the next step. Mmc12/24/48 and 
Moc12/24/48 formulations were selected, because Mmc had a higher amount of FD-4 
released and Moc contained an unsaturated fatty acid. FD-4 solution and M were also 290 
administered for comparison. 
Figure 8 shows the concentration profiles of FD-4 after s.c. injection of Mmc (a) 
and Moc (b) into rats. FD-4 solution was also injected for comparison. When FD-4 
solution was administered, a higher blood concentration of FD-4 (5282 ± 1761 ng/mL) 
was observed 30 min after administration. However, the blood concentration decreased 295 
rapidly, and was not detected 24 h after administration (the lower limitation of detection 
of FD-4 was less than 10 ng/mL). When Mmc and Moc were administered, on the other 
hand, the maximum blood concentration (Cmax) was lower than that obtained with FD-4 
solution (M; 762.7 ± 300 ng/mL at 60 min, Mmc12; 1178 ± 300 ng/mL at 30 min, Mmc24; 
2534 ± 1174 ng/mL at 30 min, Mmc48; 1300 ± 617.2 ng/mL at 60 min, Moc12; 1257 ± 300 
907.6 ng/mL at 30 min, Moc24; 1266 ± 635.6 ng/mL at 30 min, and Moc48; 1383 ± 599 
ng/mL at 60 min). Furthermore, FD-4 was detected at least 48 h after administration for 
MGE formulations. No significant difference in FD-4 concentration was observed 





Many reports have been published where cubic and reverse hexagonal liquid 
crystal structures (Q2 and H2, respectively) were used as a raw material to develop useful 310 
drug delivery systems (Báez-santos et al., 2016; Ki et al., 2014; Liang et al., 2017; Kim 
et al., 2014). Unlike closed bilayer structures such as liposomes, cubic and reverse 
hexagonal liquid crystal structures are non-closed type vehicles. Thus, especially for 
hydrophilic drugs, the entrapped drugs might easily leak from the vehicles, leading to 
disadvantages such as low biomembrane permeation and physicochemical instability of 315 
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the drugs. To overcome these problems, formulations containing self-organizing NLLC 
compounds must be improved. In addition, low-viscosity NLLC-forming lipids may be 
preferable for designing drug delivery systems for injectable, nasal, and oral cavity 
administration (Chang and Bodmeier., 1998; Nguyen et al., 2011; Yang, 2014). In the 
present study, injectable formulations consisting of an NLLC-forming lipid, MGE, with 320 
phospholipids were designed, and the effect of phospholipids in the MGE formulation 
was evaluated on the drug release and blood absorption profiles. 
The cumulative amount of FD-4 released from the MGE formulation was 
successfully expressed using eq. 1. NLLC has been receiving increasing attention as a 
novel controlled-release carrier, because the drug release rate is closely related to the 325 
crystalline phase structure and interplanar spacing for its lattice structure (Clogston and 
Caffrey, 2015; Clogston et al., 2005; Dellinger and Braun, 2004; Martiel et al., 2014).  
A CPP is used to predict which phase structure may be preferentially formed by 
a given lipid (Garti et al., 2014). In the reverse hexagonal phase, H2, one cylinder is 
present per unit cell center. The densely packed, straight and water-filled cylinders exhibit 330 
two-dimensional ordering. Each cylinder is surrounded by a layer of surfactant molecules 
perpendicular to the cylinder interface such that their hydrophobic moieties are positioned 
outwards from the water rod. On the other hand, the reverse cubic bicontinuous phase has 
two water channels. These are consecutive but not crossed, and are separated by a lipid 
bilayer. Consequently, the release rates of entrapped drugs are faster in the order lamellar 335 
phases, cubic phases, hexagonal phases, and micellar cubic (Huang and gui, 2018; Zebara 
and Mezzenga, 2014). 
In the present study, the cumulative amount of FD-4 released from the MGE 
formulations was related to the interplanar spacing. Furthermore, a good model to express 
FD-4 release from the formulations can be estimated using the following parameters; 340 
interplanar spacing, MGE content, phospholipid content, number of carbon chains in the 
phospholipid, and number of double bonds in the carbon chain. According to eq.1 as 
above, MGE content, phospholipid content, and the number of carbon chains in the 
phospholipid acted as negative factors, whereas pore spacing distance and the number of 
double bonds in the carbon chain were selected as positive factors. Fong et al. reported 345 
slower drug release from the H2 phase than from the Q2 phase (Fong and Le, 2012). In 
the present study, the NLLC structure constructed by MGE was H2 phase. Higher MGE 
content suppressed the FD-4 release. Thus, MGE content was selected as a negative factor. 
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The amount of FD-4 released decreased with an increase in the lipid chain length. Because 
the CPP values of DMPC, DPPC, and DSPC are almost the same (1/2 < CPP<1) (Guo et 350 
al., 2014), it was difficult to explain the relationship between the decreased release of FD-
4 and the hydrocarbon chain length of phospholipids in the formulation. However, longer 
hydrocarbon chains have higher van der Waals interactions. Thus, a decrease in the 
mobility of hydrocarbon chains in phospholipids is probably related to the decreased 
release of FD-4. Phospholipids with unsaturated lipid chains have a larger CPP than those 355 
with saturated lipid chains, because they bend at the position of the double bond to form 
an open structure (Zhai et al., 2017). A loose membrane structure caused by DOPC may 
be the reason for increased FD-4 release compared with that from the formulation 
containing DSPC. Thus, the addition of phospholipid into MGE may be useful to prepare 
injectable formulations to achieve the controlled release of middle- to high-molecular 360 
weight drugs. 
A sponge-like gel was obtained after s.c. administration of the MGE formulation, 
suggesting that the formulation can form an NLLC structure in the subcutis, although 
freely available fluid in the tissue is slightly different to the in vitro conditions as used in 
the in vitro release tests and SAXS observations. In addition, the gel was confirmed to 365 
retain its shape at least for 7 days. The self-organization process with MGE may begin 
from the interface between MGE. Then, when the structural organization is fully formed, 
the main pathway for FD-4 release should be continuous aqueous channels in the NLLC 
that connect to the dispersion phase or skin tissue. The blood concentration of FD-4 after 
s.c. administration of the Mmc and Moc formulations was significantly prolonged 370 
compared with that of its solution. However, no significant difference was found in the 
FD-4 concentration in blood between them. 
Low molecular compounds (<1 kDa) are rapidly taken up into the systemic 
circulation from blood capillaries after s.c. injection, whereas the rate of absorption of 
middle- to high-molecular weight compounds such as peptides is typically low, as shown 375 
by their prolonged terminal half-life (Jin et al., 2015). Systemic absorption of middle- to 
high-molecular weight compounds is restricted by their limited permeability across the 
vascular endothelium, and in this case, the lymphatic system may provide an alternative 
absorption pathway (Harvey et al., 2011). Thus, the slower rate of lymphatic absorption 
decreases blood concentration.  380 
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Throughout in vivo experiment, no severe toxicities were detected (no weight 
loss, no respiratory failure and no inflammation at the administrated site). However, 
further safety evaluations should be carried out to ensure the usefulness of this MGE as 
a pharmaceutical excipient for a depot formulation. 
 385 
5. Conclusion 
Injectable MGE formulations with phospholipids prepared in the present study 
successfully constructed NLLC structures after s.c. injection. In in vitro conditions, the 
amount of an entrapped hydrophilic high molecular weight molecule, FD-4, released from 
the NLLC structure was changed by adding phospholipid to the formulations and can be 390 
expressed with selected parameters such as MGE content and interplanar spacing. The 
formulation formed a sponge-like gel in the subcutaneous layer after injection, and the 
sustained blood concentration of FD-4 was obtained after s.c. injection, suggesting that 
the MGE formulations can be utilized as an injectable formulation to achieve sustained 
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Figure 1 Water uptake into the MGE formulations 48 h after contact with PBS. 
Nomenclature of the formulation codes of Mαβ are as follows; M: MGE, α: type of 
phospholipid (mc: DMPC, pc; DPPC, sc: DSPC, oc: DOPC), β: concentration of 
phospholipid (12, 24, 36, and 48). 
 520 
Figure 2 Polarized image of the MGE formulations 15 min after contact with PBS. 
Formulation codes: same as in Fig. 1. 
 
Figure 3 Small-angle X-ray analysis of the MGE formulations 48 h after contact with 
PBS. Formulation codes: same as in Fig. 1. 525 
 
Figure 4 Amount of FD-4 released from the MGE formulations. Formulation codes: same 
as in Fig. 1. Each point represents the mean ± S.D. (n = 3 - 4). * p < 0.05 
 
Figure 5 Relationship between interplanar spacing and the cumulative amount of FD-4 530 
released (a) (r2=0.98) and prediction of the logarithm of the cumulative amount of FD-4 
released from the MGE formulations (b). Formulation codes: same as in Fig. 1. Line in 
Fig. 5b: log $%4!"#"$%"& = 0.434 ∙ ,- − 0.020 ∙ 01 − 0.027 ∙ 31 − 0.018 ∙ 611 +
0.304 ∙ 6% + 0.709	(r2 = 0.82). The root of mean square error (RMSE) was 0.1444. 
 535 
Figure 6 Whole animal images of rats visualized using and IVIS Spectrum 0, 1, and 2 
days after s.c. injection of M. A formulation containing FD-4 was injected and its 
localization was observed. The formulation was administered to the back of rat on the 
right side using a 1 mL-disposal syringe with a 23G needle. 
  540 
Figure 7 Distribution of FD-4 (a and b) and constructed gel (c) after s.c. injection of M. 
A distribution of green color derived from FD-4 was confirmed 1 h (a) and 24 h (b) after 
administration. The constructed gel was collected from the administration site 48 h after 
s.c. injection in rats. 
 545 
 20 
Figure 8 Time course of blood concentration of FD-4 after s.c. injection of Mmc (a) and 
Moc (b) formulations in rats. Symbols in (a); : FD-4 solution, : M, r: Mmc12, ¯: 
Mmc24, and £: Mmc48. Symbols in (b); : FD-4 solution, : M, p: Moc12, u: Moc24, 
and ¢: Moc48. Each point represents the mean ± S.D. (n = 3 - 4).  

























































































































































































































































































































































































   






















Table 2 Constructed liquid crystal structure and interplanar spacing 
of the formulations 
Formulation Liquid crystal structure d (nm) 
M H2 4.36 
Mmc12 Pn3m 5.33 
Mmc24 Pn3m 6.42 
Mmc36 Pn3m 7.39 
Mmc48 Pn3m 6.76 
Mpc12 Pn3m 5.32 
Mpc24 Pn3m 6.34 
Mpc36 Pn3m 7.39 
Msc12 H2 4.87 
Msc24 H2 + Pn3m 5.49 
Msc36 Pn3m 6.61 
Moc12 H2 4.65 
Moc24 H2 4.95 
Moc36 Pn3m 6.28 
The relative positions of the Bragg peaks are in a ratio of √ 2:√ 3:√ 4 showing Pn3m structure. The 
spacing ratio of 1:!1 3$ :!1 4$ :!1 7$  shows H2 structure. The peak positions were calculated with 
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Fig. 7 
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